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ABSTRACT 
Solution chemical properties of two bidentate pyrazolyl thiosemicarbazones 2-((3-methyl-1-
phenyl-1H-pyrazol-4-yl)methylene)hydrazinecarbothioamide (Me-pyrTSC), 2-((1,3-diphenyl-
1H-pyrazol-4-yl)methylene)hydrazinecarbothioamide  (Ph-pyrTSC), stability of their Cu(II) 
and Ru(6-p-cymene) complexes were characterized in aqueous solution (with 30% DMSO) 
by the combined use of UV-visible spectrophotometry, 
1
H NMR spectroscopy and 
electrospray ionization mass spectrometry in addition to their solid phase isolation. The solid 
phase structures of Me-pyrTSC∙H2O, [Ru(
6
-p-cymene)(Me-pyrTSC)Cl]Cl and [Cu(Ph-
pyrTSCH‒1)2] were determined by single crystal X-ray diffraction. High stability mononuclear 
Ru(6-p-cymene) complexes with (N,S) coordination mode are formed in the acidic pH range, 
and increasing the pH the predominating dinuclear [(Ru(6-p-cymene))2(L)2]
2+
 complex with 
2-bridging sulphur donor atoms is formed (where L
-
 is the deprotonated thiosemicarbazone). 
[CuL]
+
 and [CuL2] complexes show much higher stability compared to that of complexes of 
the reference compound benzaldehyde thiosemicarbazone. [CuL2] complexes predominate at 
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neutral pH. Me-pyrTSC and Ph-pyrTSC exhibited moderate cytotoxicity against human 
colonic adenocarcinoma cell lines (IC50 = 33-76 M), while their complexation with Ru(
6
-p-
cymene) (IC50 = 11-24 M) and especially Cu(II) (IC50 = 3-6 M) resulted in higher 
cytotoxicity. Cu(II) complexes of the tested thiosemicarbazones were also cytotoxic in three 
breast cancer and in a hepatocellular carcinoma cell line. No reactive oxygen species 
production was detected and the relatively high catalase activity of SUM159 breast cancer 
cells was decreased upon addition of the ligands and the complexes. In the latter cell line the 
tested compounds interfered with the glutathione synthesis as they decreased the 
concentration of this cellular reductant.     
 
1. Introduction 
Thiosemicarbazones (TSCs) are versatile compounds and known for their wide 
pharmacological activity including anticancer properties [1,2]. Triapine (3-aminopyridine-2-
carboxaldehyde thiosemicarbazone) is the best-known representative of this family and was 
extensively investigated in numerous clinical phase I and II trials in mono or combination 
therapies [3,4]. Two new promising TSCs, namely N'-(6,7-dihydroquinolin-8(5H)-ylidene)-4-
(pyridin-2-yl)piperazine-1-carbothiohydrazide (COTI-2, an orally available third generation 
TSC) and di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) also entered 
human clinical studies in the last years [5,6]. These compounds belong to the family of -N-
pyridyl TSCs, therefore are considered as tridentate ligands with a typical (Npyridyl,N,S) 
coordination mode with strong affinity towards various metal ions including Fe(II/III) and 
Cu(II) [7]. The anticancer properties of Triapine are connected to the inhibition of the iron-
containing ribonucleotide reductase enzyme and the formation of redox-active iron complexes 
in the cells is suggested to be a crucial step of the mechanism of action [8]. On the other hand, 
other essential metal ions (especially copper) besides iron have been associated with the 
mechanism of action of TSCs [9-11]. -N-pyridyl- and salicylaldehyde-type TSCs are able to 
form mono-ligand Cu(II) complexes with high solution stability at physiological pH with 
(Npyridyl,N,S
‒
) and (O
‒
,N,S
‒
) coordination modes, respectively [12-14]. Till now numerous 
Cu(II) complexes of TSCs were developed for anticancer activity [15,16] and generation of 
reactive oxygen species (ROS) is often assumed to be the mode of action [17,18], although it 
is not true in all cases [7,19]. In addition to Cu(II) other metal ions such as Pd(II), Ga(III), 
half-sandwich organometallic ions [15,20-23] can also form complexes with TSCs owing 
significant cytotoxicity via different mechanisms of action and multiple targets. 
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For understanding of the anticancer activity of TSCs and their metal complexes and 
for investigation of structure-activity relationships the knowledge on their solution speciation 
and the most probable solution structures under physiological conditions is of primary 
importance. The anticancer TSC compounds are often characterized only in solid phase or in 
organic solvents, and information about their behaviour in aqueous solution is still limited. 
Although solution speciation of numerous Cu(II) and Fe(II)/III) complexes of -N-pyridyl- 
and salicylaldehyde-type TSCs was determined in our previous works [12-14,24], no 
available stability data are published for the complexes of bidentate TSCs so far. In this work 
our aim was to reveal the differences of the complex formation with Cu(II) ions between two 
bidentate pyrazolyl TSCs Me-pyrTSC, Ph-pyrTSC (Chart 1) and tridentate TSCs, and to 
characterize the complexation of these ligands with the half-sandwich organometallic 
[Ru(6-p-cymene)(H2O)3]
2+
. The bis-ligand Pd(II) complexes of them were reported to be 
rather cytotoxic against MCF7 breast cancer cell lines (IC50 = 0.57-1.24 M) [25], but no 
cytotoxicity data were published for their Cu(II) and Ru(6-p-cymene) complexes. 
 
 
Chart 1. Chemical structures of the investigated 2-((3-methyl-1-phenyl-1H-pyrazol-4-
yl)methylene)hydrazinecarbothioamide (Me-pyrTSC), 2-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)hydrazinecarbothioamide (Ph-pyrTSC) and 2-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)hydrazinecarboxamide (Ph-pyrSC) in their neutral forms (HL). 
 
Therefore, solution speciation, solid phase structures of Cu(II) and Ru(6-p-cymene) 
complexes of the selected bidentate pyrazolyl TSCs were investigated by different methods 
such as UV-visible (UV-vis) spectrophotometry, 
1
H , 
13
C NMR and electron paramagnetic 
resonance (EPR) spectroscopy, electrospray ionization mass spectrometry (ESI-MS) and X-
ray crystallography. Additionally, anticancer activity via cytotoxicity assays, ROS production, 
catalase activity and L-glutathione (GSH) levels were also monitored.       
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2. Experimental 
2.1. Chemicals 
All solvents were of analytical grade and used without further purification. All solvents used 
for the ligand synthesis were distilled shortly prior to use. [Ru(6-p-cymene)(-Cl)Cl]2, 
benzaldehyde thiosemicarbazone (Bz-TSC), CuCl2, KCl, HCl, KOH, NaH2PO4, Na2HPO4, 
dimethyl sulfoxide (DMSO), EDTA, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), maltol, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), N-
acetyl-cysteine (NAC), 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), 2,2'-dinitro-
5,5'-dithiodibenzoic acid (DTNB) and 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) were 
purchased from Sigma-Aldrich in puriss quality. Milli-Q water was used for sample 
preparation. CuCl2 stock solution was made by the dissolution of anhydrous CuCl2 in water 
and its exact concentration was determined by complexometry through the EDTA complex. 
The exact concentration of aqueous stock solution of Ru(6-p-cymene) prepared by the 
dissolution of [Ru(6-p-cymene)(-Cl)Cl]2 was determined by pH-potentiometric titrations in 
the presence of 0.2 M chloride ions employing stability constants for [(Ru(6-p-
cymene))2(-OH)i]
(4-i)+
 (i = 2 or 3) complexes [26]. The stock solution of Bz-TSC and Ph-
pyrSC was prepared on a weight-in-volume basis dissolved in DMSO, while the purity of Me-
pyrTSC and Ph-pyrTSC was checked by 
1
H NMR spectroscopy in DMSO-d6 using maltol as 
internal standard. 
 
2.2. Synthesis of Me-pyrTSC, Ph-pyrTSC and Ph-pyrSC 
Compounds Me-pyrTSC, Ph-pyrTSC and Ph-pyrSC were prepared according to the literature 
[27,28] with some modifications. The synthetic route (Scheme S1) and characterization of the 
products are found in the Supplementary Information. General procedure for the synthesis of 
hydrazones (2a and 2b): phenylhydrazine (1.18 mL, 12.0 mmol) and a catalytic amount of 
acetic acid (0.1 mL) were added to a solution of acetone (1a, 0.74 mL, 10.0 mmol) or 
acetophenone (1b, 1.17 mL, 10.0 mmol) in ethanol (EtOH) (10 mL). The reaction mixture 
was kept at reflux temperature for 1 h and then cooled to 25 °C. The progress of the reaction 
was monitored by thin-layer chromatography (TLC) (ethyl acetate (EtOAc)/hexane=10:90). 
The resulting precipitate was filtered off and washed with a small amount of ice-cold 
methanol, then dried under vacuo. The product decomposes at room temperature or above and 
should be kept in a refrigerator. 
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Synthesis of 4-formyl pyrazoles (3) (Vilsmeier-Haack reaction): To an ice-cold solution 
of 2a (0.74 g, 5.0 mmol) or 2b (1.05 g, 5.0 mmol) in N,N-dimethylformamide (DMF, 20 mL), 
cold phosphoryl chloride (POCl3, 3 equiv.) was added dropwise, and the mixture was first 
stirred at 0 °C for 10 min and then was heated to 60 °C and kept at this temperature for 3 h. 
The progress of the reaction was monitored by TLC (EtOAc/hexane = 20:80). After cooling, 
the mixture was poured into ice-cold water (100 mL), neutralized with NaOH aqueous 
solution, and the precipitate was filtered in vacuo, washed with water and crystallized from 
EtOH. 
Synthesis of Me-pyrTSC and Ph-pyrTSC: To a solution of 3a (186 mg, 1.0 mmol) or 3b 
(248 mg, 1.0 mmol) in EtOH (5 mL), a catalytic amount of glacial AcOH (0.1 mL) and 
thiosemicarbazide (109 mg, 1.2 equiv.) were added, and the reaction mixture was irradiated 
with microwave (MW) (80 °C) for 5 min (alternatively 2 h under reflux is sufficient). The 
completion of the reaction was determined by TLC (EtOAc/hexane = 40:60). The crude 
product was poured into ice cold water. The solid thus obtained was filtered in vacuo, washed 
with ice-cold water and purified by column chromatography (silica gel, EtOAc/hexane=30:70 
to EtOAc using gradient elution). 
Procedure for the synthesis of Ph-pyrSC: To a solution of 2b (248 mg, 1.0 mmol) in 
EtOH (5 mL), semicarbazide hydrochloride (134 mg, 1.2 equiv.) and NaOAc (98 mg, 
1.2 equiv.) were added, and the reaction mixture was irradiated with MW (80 °C) for 5 min 
(alternatively 2 h under reflux is sufficient). The completion of the reaction was determined 
by TLC (EtOAc/hexane = 40:60). The crude product was poured into ice-cold water. The 
solid thus obtained was filtered in vacuo, washed with ice-cold water and purified by column 
chromatography (silica gel, EtOAc). 
Reactions under MW-irradiation were carried out with a CEM Discover SP equipment 
using dynamic control program with a maximum power of 200 Watts. Reactions were 
monitored by thin layer chromatography on Kieselgel-G (Merck Si 254 F) layers (0.25 mm 
thick). Flash chromatography: Merck silica gel 60, 40–63 μm. Melting points were 
determined on an SRS Optimelt digital apparatus.  
 
2.3. Synthesis of Ru(η6-p-cymene) and Cu(II) complexes of Me-pyrTSC and Ph-pyrTSC 
[Ru(η6-p-cymene)(Me-pyrTSC)Cl](Cl) and [Ru(η6-p-cymene)(Ph-pyrTSC)Cl](Cl) 
complexes: Me-pyrTSC (0.062 mmol) or Ph-pyrTSC (0.062 mmol) and [Ru(η6-p-cymene)(-
Cl)Cl]2 (0.031 mmol) were dissolved in 2.0 mL ethanol, then 4.5 mL water was added. 
Solvent mixture was evaporated at room temperature for 5 days. Complexes were re-
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crystallized from CH2Cl2, and the complex was obtained as dark red solid powder (yield: 27% 
for Me-pyrTSC and 23% for Ph-pyrTSC complexes, respectively). The isolated complexes 
were characterized by ESI-MS, 
1
H and 
13
C NMR spectroscopy and UV-vis 
spectrophotometry; see experimental data and spectra (Figures S1-S3) in SI. 
[Cu(Me-pyrTSCH‒1)2] and [Cu(Ph-pyrTSCH‒1)2]: The ligand Me-pyrTSC (0.084 mmol) or 
Ph-pyrTSC (0.084 mmol) was dissolved in DMSO (3.0 mL), then 0.7 mL 0.05 M HCl and 
CuCl2 solution (86.39 M in water, 0.042 mmol) was added, and the pH was adjusted to pH 
~ 6 by the addition of 0.1 M KOH (0.8 mL). Pale brownish precipitate was formed. The 
precipitate was decanted, washed with 5-5 mL water four times and dried at 80 °C overnight. 
Formed complexes (yield: 29% for Me-pyrTSC and 25% for Ph-pyrTSC) were characterized 
by ESI-MS, EPR spectroscopy and UV-vis spectrophotometry, see experimental data and 
spectra (Figures S4-S6) in SI. 
 
2.4. Crystallographic structure determination 
Single crystals suitable for X-ray diffraction experiment of ligand Me-pyrTSC∙H2O (I), 
complexes [Ru(6-p-cymene)(Me-pyrTSC)Cl]Cl (II) and [Cu(Ph-pyrTSCH‒1)2] (III) were 
grown from ethanol:CH2Cl2 (1:1) (I) or ethanol:water (3:7) (II) or DSMO:CH2Cl2 (2:5) (III) 
solvent mixtures containing Ru(6-p-cymene) and Me-pyrTSC at 1:1 (II), or Cu(II) and Ph-
pyrTSCS at 1:2 (III) metal-to-ligand ratio, respectively. Single crystals were mounted on loops 
and transferred to the goniometer. X-ray diffraction data were collected at low temperature 
(128, 153 and 108 K for crystals I, II and III respectively) on a Rigaku RAXIS-RAPID II 
diffractometer using Cu-Kradiation for crystal I and Mo-K radiation for crystals II and III. 
Numerical (for crystal I) or empirical (for crystal II and III) absorption correction [29] were 
carried out using the program CrystalClear [30]. Sir2014 [31] and SHELXL [32] under WinGX
 
software [33] were used for structure solution and refinement, respectively. The structures 
were solved by direct methods. The models were refined by full-matrix least squares on F
2
. 
Refinement of non-hydrogen atoms was carried out with anisotropic temperature factors. 
Hydrogen atoms were placed into geometric positions (except for water hydrogens). They were 
included in structure factor calculations but they were not refined. The isotropic displacement 
parameters of the hydrogen atoms were approximated from the U(eq) value of the atom they 
were bonded to. For crystal I the collection of high angle data was limited because of the use of 
copper wavelength. For crystal II disordered structures were detected therefore some non-
hydrogen atoms were also treated with isotropic displacement parameters. In case of crystal III 
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the platelet crystal shape prevented the collection of high quality data. The summary of data 
collection and refinement parameters are collected in Table S2. Selected bond lengths and 
angles of compounds were calculated by PLATON software [34]. The graphical representation 
and the edition of CIF files were done by Mercury [35] and PublCif [36] softwares. The 
crystallographic data files for the complexes have been deposited with the Cambridge 
Crystallographic Database as CCDC 1942252-1942254. 
 
2.5. Solution studies: pH-potentiometry, UV-visible and 
1
H NMR spectroscopy, ESI-MS 
The pH-potentiometric titrations for the determination of the exact concentration of the HCl 
and KOH solutions, the overall stability constant of [((Ru(6-p-cymene))2(-OH)3]
+
 species 
were carried out at 25.0 ± 0.1 
o
C in DMSO:water 30:70 (v/v) as solvent. Ionic strength of 
0.10 M (KCl) was used in order to keep the activity coefficients constant. The titrations were 
performed with carbonate-free KOH solution of known concentration (0.10 M). An Orion 
710A pH-meter equipped with a Metrohm combined electrode (type 6.0234.100) and a 
Metrohm 665 Dosimat burette were used for the titrations. The electrode system was 
calibrated to the pH = −log[H+] scale in the DMSO/water solvent mixture by means of blank 
titrations (strong acid vs. strong base: HCl vs. KOH), similarly to the method suggested by 
Irving et al. [37] in pure aqueous solutions. The average water ionization constant pKw was 
14.55 ± 0.02, which corresponds well to the literature data [12-14,38]. The pH-potentiometric 
titrations were performed in the pH range 2.0 − 12.5 using 10 cm3 sample volumes. The 
concentration of the [(Ru(6-p-cymene)(H2O)3]
2+ 
was 2 mM. Samples were deoxygenated by 
bubbling purified argon through them for approximately 10 min prior to the measurements. 
Argon was also passed over the solutions during the titrations. Calculation of the 
stoichiometry and stability constants of the complexes was performed with the computer 
program HYPERQUAD [39].  
An Agilent Cary 8454 diode array spectrophotometer was used to record the UV-vis 
spectra in the 200 to 950 nm window. The path length was varied between 1 and 50 mm. 
Equilibrium constants and the molar absorbance spectra of the individual species were 
calculated with the computer program PSEQUAD [40]. The spectrophotometric titrations were 
performed on samples containing the ligands with or without metal ions in the pH range from 
2 to 12.5 at 25.0 ± 0.1 °C in DMSO:water 30:70 (v/v) at an ionic strength of 0.10 M (KCl). 
The concentration of the ligands was in the range 2‒ 160 M; the metal-to-ligand ratios were 
varied between 1:0.25 ‒ 1:5.  
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Distribution coefficient (D7.4) values of ligands were determined by the traditional 
shake-flask method in n-octanol/buffered aqueous solution at pH 7.40 (20 mM phosphate 
buffer, 0.10 M KCl) at 25.0 ± 0.2 °C as described previously with some modifications [41]. 
The ligands were dissolved at 50 M concentrations in n-octanol pre-saturated with buffer 
solution. The aqueous solution and n-octanol (1:1 ratio) were gently mixed with 360° vertical 
rotation (~20 rpm) for 3 h to avoid emulsion formation, and the mixtures were centrifuged at 
5000 rpm for 3 min. After separation, UV-vis spectra of the compounds in the n-octanol phase 
were compared to those of the original n-octanol solutions and D7.4 values were calculated as 
follows: Absorbance (n-octanol phase after separation) / (Absorbance (original n-octanol 
solution) ‒ Absorbance (n-octanol phase after separation)). 
1
H and 
13
C NMR spectroscopic studies for the ligands and the Ru(6-p-cymene) 
complexes were carried out on a Bruker Avance III HD Ascend 500 Plus instrument. Spectra 
were recorded in CDCl3, in DMSO-d6 or in a 30% (v/v) DMSO-d6/H2O mixture using 0.5 ‒ 2 
mM ligand concentrations varying the metal-to-ligand ratios, the pH (2 ‒ 12) or the chloride 
ion content. In the latter case DMSO-d6 was used as reference (δ = 2.65 ppm) and 
WATERGATE method was used to suppress the solv nt resonance. 
ESI-MS measurements were performed using a Waters Q-TOF Premier (Micromass MS 
Technologies, Manchester, UK) mass spectrometer equipped with electrospray ion source. 
Samples contained 20-50 M complex dissolved in methanol or 5 M Ru(6-p-cymene) 
organometallic cation and 5‒ 20 M ligand in 2% (v/v) ethanol/water solvent mixture. pH 
was adjusted by small amount of formic acid, HCl or KOH. 
 
2.6. In vitro cell studies 
Cell lines and culture conditions: All cell culture reagents were obtained from Sigma-Aldrich 
and plastic ware from Sarstedt (Germany). Human colonic adenocarcinoma cell lines Colo 
205 doxorubicin-sensitive and Colo 320/MDR-LRP multidrug resistant, overexpressing 
ABCB1 (MDR1)-LRP, ATCC-CCL-220.1 (Colo 320) and CCL-222 (Colo 205) were 
purchased from LGC Promochem, Teddington, UK. MRC-5 human embryonal lung fibroblast 
cell line (ATCC CCL-171) was purchased from LGC Promochem, Teddington, UK. In 
addition, hepatocellular carcinoma cell line (HepG2) and three subtypes of breast cancer cell 
lines: the hormone-responsive MCF7, the HER2-positive SkBr3 and the triple-negative 
SUM159 cancer cell lines were also used. The cells were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium for Colo and MRC-5 or in Dulbecco’s modified Eagle’s 
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medium (DMEM) for HepG2 and breast cancer cell lines supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 100 mM 
HEPES. The cells were incubated at 37°C, in a 5% CO2, 95% air atmosphere. All cell lines 
were detached with Trypsin-Versene (EDTA) solution for 5 min at 37 °C. 
MTT and EZ4U assays: Me-pyrTSC, Ph-pyrTSC, Ph-pyrSC and their copper(II) and 
Ru(6-p-cymene) complexes were dissolved in a 90% (v/v) DMSO/H2O mixture first using 
10 mM ligand and 0, 5 or 10 mM metal ion concentrations. The metal salts without ligands 
were also tested. Cisplatin (Teva) was used as a positive control. Then stock solutions were 
diluted in complete culture medium, and two-fold serial dilutions of compounds were 
prepared in 100 L of RPMI 1640, horizontally. The semi-adherent colonic adenocarcinoma 
cells were treated with Trypsin-Versene (EDTA) solution. They were adjusted to a density of 
1×10
4
 cells in 100 L of RPMI 1640 medium, and were added to each well, with the 
exception of the medium control wells. The final volume of the wells containing compounds 
and cells was 200 L. The culture plates (Colo205, Colo320, MRC-5) were incubated at 37°C 
for 72 h; at the end of the incubation period, 20 L of MTT solution (from a stock solution of 
5 mg/mL) were added to each well. After incubation at 37°C for 4 h, 100 L of SDS solution 
(10% in 0.01 M HCI) were added to each well and the plates were further incubated at 37˚C 
overnight. The EZ4U assay kit (Biomedica, Wien, Austria) was used according to 
manufacturer’s instructions in the case of cell lines HepG2, MCF7, SkBr3 and SUM159.  
Samples and cells were prepared in the similar way as in case of the traditional MTT assay. 
After the 24 h incubation the compounds were diluted in a volume of 100 µL medium, then 
the culture plates were incubated at 37 C for 24 h; at the end of the incubation period, 20 µL 
of MTT solution was added to each well and incubated for 2 h incubation. The cell growth 
was determined using both methods by measuring the optical density (OD) at 450 nm (ref. 
620 nm) with a Multiscan EX ELISA reader. Inhibition of the cell growth (expressed as IC50: 
inhibitory concentration that reduces by 50% the growth of the cells exposed to the tested 
compounds) was determined from the sigmoid curve where 100 - ((ODsample ‒ ODmedium control) 
/ (ODcell control ‒ ODmedium control))×100 values were plotted against the logarithm of compound 
concentrations. Curves were fitted by GraphPad Prism software [42] using the sigmoidal 
dose-response model (comparing variable and fixed slopes). 
Reactive oxygen species production assay: The ROS measurement was performed in 
MCF7 and SUM159 cell lines with 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). 
While penetrating the cell DCFH-DA is deacetylated by esterases and the forming DCFH 
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inside the cell reacts with ROS and transforms to the fluorescent 2,7-dichlorofluorescein 
(DCF) in turn. The emission intensity of DCF was measured at 529 nm using 500 nm 
excitation wavelength. The SkBr-3 and HepG2 cancer cells were seeded 1×10
4
 in 100 µL 
DMEM /10% fetal bovine serum (FBS) into in 96-well microtiter plates. After allowing cells 
to adhere for 24 h, 1 mM NAC was added to some wells while 100 µM DCFH-DA was added 
to all wells. After removing the media with the excess of DCFH-DA, cells were treated with 
the compounds in 1 µM concentration (where the compounds are not toxic to the cells). The 
increase in ROS caused by compounds applied was measured at different time points – prior 
to treatment and 120 min after the treatment.  
Catalase activity and GSH level assays: For both assays cells were prepared in a same 
manner. The SUM159 and MCF-7 were seeded in 6-well plates at density of 5×10
5
 cell/well, 
and were allowed 24 h to attach to the well. Then, cells were treated with 1 µM compound 
and left for 24 h after which they were harvested, and the dry pellet was stored at -80 C until 
analysis. For analyses, cells were lysed in phosphate buffered saline (PBS) by 4 freeze/thaw 
cycles, and total protein content was measured by Bradford method [43]. Total GSH was 
measured spectrophotometrically at 450 nm (ref. 620 nm) by modified Tietze method based 
on reduction of DTNB (Ellman's reagent) to 2-nitro-5-thiobenzoate (TNB anion) by GSH 
[44]. Catalase activity was assayed by measuring H2O2 decomposition by catalase in the 
whole cell lysate by Góth method [45]. 
 
3. Results and discussion 
 
3.1. Synthesis, solid and solution phase characterization of Me-pyrTSC, Ph-pyrTSC and Ph-
pyrSC 
Compounds Me-pyrTSC, Ph-pyrTSC and Ph-pyrSC (Chart 1) were prepared by the 
condensation reaction of the corresponding 4-formyl pyrazoles (pyrazole-4-carbaldehyde) and 
thiosemicarbazide or semicarbazide hydrochloride as described in references [27,46], 
although some modifications were applied, namely microwave-assisted reactions were 
performed (Scheme S1). Acid-catalyzed condensation reaction of acetone (1a) or 
acetophenone (1b) with phenylhydrazine in refluxing ethanol led to the corresponding 
hydrazones (2a and 2b) in excellent yields. Subsequent cyclization and simultaneous 
formylation with the Vilsmeier-Haack reagent (POCl3/DMF) afforded 4-formyl-pyrazoles (3a 
and 3b) [46], which were then converted to thiosemicarbazones (Me-pyrTSC and Ph-pyrTSC) 
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and a semicarbazone (Ph-pyrSC), respectively, in the presence of acetic acid (Me-pyrTSC and 
Ph-pyrTSC) or sodium acetate (Ph-pyrSC) [27] in ethanol under MW irradiation. 
1
H and 
13
C 
NMR spectra were in agreement with the expected structures of the intermediates and the 
final products and the 
1
H and 
13
C resonances published previously [27,46-50] (see 
Supplementary Information). 
The structure of Me-pyrTSC∙H2O (I) was established by single crystal X-ray diffraction 
(Figure 1.a). Me-pyrTSC crystallized in monohydrate form in triclinic P-1 space group. The 
molecule has a twisted conformation as ring A is twisted from ring B by 27.99(13)
o
 and plane 
C is twisted from ring B by 29.5
o 
(Figure 1.b). An intramolecular hydrogen bond between N5-
H5A…N3 stabilizes the molecular conformation. In the crystal, dimers are formed between 
two molecules via the N5-H5B…S1 hydrogen bonds, and vice versa (Figure S7). The 
neighbouring molecules are further connected through hydrogen bonds with solvent water 
molecules. The acidic hydrogen, H2N4 is coordinating to a water oxygen, and water hydrogens 
are connected to N2 and S1 atoms. The packing arrangement is shown in Figure S7. Selected 
H-bond distances and angles are collected in Table S3. Apart from hydrogen bonds a … 
(off-centered parallel stacking) interaction could b  observed between the two five membered 
rings for which the distance of 3.8687(14) Å can be measured. 
 
 
 
Figure 1. (a) Molecular structure of Me-pyrTSC∙H2O (I). Displacement parameters are drawn at 50% 
probability level. Hydrogen atoms are omitted for clarity. (b) Conformation of the compound and 
assignment of the molecular planes. 
 
The molecular structure of Me-pyrTSC∙H2O (I) was compared with Ph-pyrTSC 
A
BC
a)
b)
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(PIKRUX) [51] and two other pyrazolyl TSC derivatives (Ref. codes: CEHHEE and XEBCIS) 
defined previously [52,53]. CEHHEE also crystallized with one water molecule, while 
PIKRUX and XEBCIS crystallized without solvent inclusion in their crystal lattices. When the 
pyrazole rings are overplayed high flexibility of the hydrazine-carbothioamide side chain can 
be seen for the different crystals (Figure S8). 
Since the TSCs and their metal complexes showed much more significant cytotoxicity 
than the semicarbazone Ph-pyrSC (vide infra), our solution studies were focused on the 
behaviour of Me-pyrTSC and Ph-pyrTSC. The purity of Me-pyrTSC and Ph-pyrTSC was also 
checked via 
1
H NMR spectroscopic measurements using maltol as internal standard. The solid 
ligand was dissolved in DMSO-d6 and different amounts of maltol were added (Figure S9), 
then the peak integrals of the ligand were compared to those of maltol of known 
concentrations. The compounds were found to be adequately pure (98.5-100%) and the exact 
concentrations of their stock solutions prepared on a weight-in-volume basis were calculated 
taking notice of these values.    
The studied compounds have limited water solubility that hindered the use of pH-
potentiometric titrations, therefore the proton dissociation processes of Me-pyrTSC and Ph-
pyrTSC were studied by UV-vis spectrophotometry at low ligand concentration in 30% (v/v) 
DMSO/water solvent mixture, similarly to our former works [12-14,24] to obtain comparable 
data. In addition Bz-TSC was involved as a simple bidentate TSC model for comparison. No 
spectral changes were observed up to pH 10 (Figure 2), and the appearance of a well-defined 
isobestic point at higher pH values demonstrates that two species (HL, L
‒
) are involved in the 
equilibrium. pKa values and the spectra of the individual ligand species were calculated on the 
basis of deconvolution of recorded UV-vis spectra (Table 1). The deprotonation process can 
be attributed to the hydrazinic-NH moiety. These TSCs have high and similar pKa values, and 
we can conclude that they are present in their HL form at neutral pH. These pKa values are 
somewhat higher than those of the -N-pyridyl TSCs such as Triapine or formaldehyde TSC 
[24]. 
1
H NMR spectra were recorded at various pH values (see the representative example for 
Bz-TSC in Figure S10) and the pH-dependence of the chemical shifts confirmed the high pKa 
values of the ligands. 
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Figure 2. UV-vis absorption spectra of Ph-pyrTSC (a) and Bz-TSC (b) in the pH range 2-14 in 
30% (v/v) DMSO/water solvent mixture in addition to the deprotonation process. {cPh-pyrTSC = 10 M; 
cBz-TSC = 47 M; T = 25.0 °C; I = 0.1 M (KCl); l = 1 cm}  
 
The lipophilic character is an important property of drugs as it strongly affects the 
passage via biological membranes. Therefore we attempted to determine the logD7.4 values for 
Me-pyrTSC, Ph-pyrTSC and Bz-TSC using the shake-flask method in n-octanol/buffered 
aqueous solution at pH 7.40 (Table 1). The logD7.4 values represent the strong lipophilic 
feature of the compounds.    
 
Table 1  
pKa values determined by UV-vis titrations, max, molar absorbance () and logD7.4 values of ligands 
studied. {T = 25 C; I = 0.1 M (KCl) in 30% (v/v) DMSO/H2O}
 
 medium Me-pyrTSC Ph-pyrTSC Bz-TSC 
pKa 30% (v/v) DMSO/H2O 11.53±0.01 11.56±0.01 11.78±0.01 
max (nm) / (M-
1
cm-
1
) 30% (v/v) DMSO/H2O 
    HL 
    L
–
 
 
313 / 37690 
330 / 26825 
 
323 / 28420 
340 / 21979 
 
310 / 31450 
338 / 21290 
 DMSO 323 / 39100 333 / 30700 - 
logD7.4 n-octanol/ buffer  > +1.9 +2.1±0.2 +1.55±0.04 
 
3.2. Solution equilibrium studies, synthesis and structural characterization of 
ruthenium(II)(6-p-cymene) complexes 
The complex formation equilibrium processes can be characterized when the 
hydrolysis constants of the organoruthenium triaqua cation are known besides the pKa 
values of the ligands under the condition applied. The hydrolytic behaviour of [Ru(6-
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260 285 310 335 360 385 410
A
b
s
o
rb
a
n
c
e
 / nm
pH = 2.44-9.63
11.88
~14
0.0
0.3
0.6
0.9
1.2
1.5
260 285 310 335 360 385 410
A
b
s
o
rb
a
n
c
e
 / nm
pH = 1.95-9.74
~13,1
a) b)
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
14 
 
p-cymene)(H2O)3]
2+
 has been already studied in pure water by Buglyó et al. at 0.2 M 
chloride ion concentration and in solutions of 0.2 M KNO3 [26,54]. In addition the 
hydrolysis constants were also determined in 20% (v/v) DMSO/water solvent mixture 
by UV-vis spectrophotometric titrations in our former work using 0.2 M KCl ionic 
strength [55]. Based on the reported constants (Table 2) it could be concluded that the 
probable coordination of chloride ions and DMSO suppresses the hydrolysis of this 
organometallic cation which is then shifted to higher pH values. In the present work 
30% (v/v) DMSO/water solvent mixture and 0.1 M KCl ionic strength was used due to 
the limited solubility of the ligands in water. The hydrolysis was followed by pH-
potentiometric, UV-vis spectrophotometric and 
1
H NMR spectroscopic titrations 
yielding equilibrium constants which are in a good agreement with each other 
(Table 2). It is important to note that as the chloride ions and DMSO are coordinating 
ligands; thus the possible partial displacement of aqua ligand by chloride or DMSO 
should be considered and all the determined equilibrium constants for the 
organoruthenium species are conditional constants obtained at the given chloride 
concentration. 
1
H NMR spectra recorded for [Ru(6-p-cymene)(H2O)3]
2+
 at various pH 
values are shown in Figure 3, which refer to the presence of only one type of 
hydrolysis product appearing at pH > 5. This species was identified as the -hydroxido 
bridged dinuclear [(Ru(6-p-cymene))2(-OH)3]
+
 as it was suggested in the previous 
works [26,54].    
 
Table 2  
Hydrolysis constants of [Ru(6-p-cymene)(H2O)3]
2+
 (log) and overall (log) and stepwise (logK) 
stability constants and proton dissociation constants (pKa) of the Ru(
6
-p-cymene) complexes formed 
with Me-pyrTSC and Ph-pyrTSC. {T = 25 C; I = 0.1 M (KCl) in 30% (v/v) DMSO/H2O}
 
 method   
log[(Ru(6-p-cymene)2(H‒1)3]
+ a
 pH-metry ‒14.69±0.05  
 UV-vis ‒14.75±0.01  
 
1
H NMR ‒14.64±0.01  
  Me-pyrTSC Ph-pyrTSC 
log[Ru(6-p-cymene)(HL)]2+/+ b UV-vis ≥19.0 ≥18.9 
pKa[Ru(
6
-p-cymene)(HL)]
2+/+
 
1
H NMR 3.50±0.02 3.44±0.02 
log[Ru(6-p-cymene)(L)]+/0 c cald. ≥15.5 ≥15.5 
logK[(Ru(6-p-cymene))2(L)2]
2+ d
 
1
H NMR 5.50±0.03 5.34±0.02 
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log[(Ru(6-p-cymene))2(L)2]
2+ e
 cald. ≥36.5 ≥36.3 
a [(Ru(6-p-cymene)2(H‒1)3]
+ = [(Ru(6-p-cymene))2(OH)3]
+. log [(Ru(6-p-
cymene))2(H-1)3]
+ = ‒9.36 (pure water, 0.2 M KNO3) [54]; = ‒11.88 (pure water, 0.2 M 
KCl) in addition to log [(Ru(6-p-cymene))2(H‒1)2]
+ = ‒7.12 [26]; = ‒15.11 (20% 
DMSO/H2O, 0.2 M KCl) in addition to log [(Ru(
6-p-cymene))2(H‒1)2]
+ = ‒9.85 [55]. b 
Estimated values. c = log[Ru(6-p-cymene)(HL)]2+/+ ‒ pKa[Ru(
6-p-cymene)(HL)]2+/+. d 
Formation from the mononuclear species. e = logK[(Ru(6-p-cymene))2(L)2]
2+ + 2× 
log[Ru(6-p-cymene)(L)]+/0. 
 
 
Figure 3. (a) Representative 
1
H NMR spectra in the low-field region recorded for [Ru(6-p-
cymene)(H2O)3]
2+
 in the pH range 3.2 ‒ 11.4 in the presence of 0.1 M chloride ions in 30% (v/v) 
DMSO-d6/water solvent mixture. Notably, the aqua ligands in the triaqua cation are partly replaced by 
chloride ions (or DMSO). (b) Calculated concentration distribution curves with the hydrolysis constant 
determined, symbols (●, □) show the values calculated on the basis of 1H NMR integrals. {cRu(6-p-
cymene) = 2.5 mM; T = 25.0 °C; I = 0.1 M (KCl)}  
 
The complex formation of [Ru(6-p-cymene)(H2O)3]
2+
 with the TSC ligands was 
found to be fairly slow according to the time-dependent UV-vis spectra recorded at pH 
2.5 and 7.4 (see Figure S11 in case of Me-pyrTSC). The chemical equilibrium was 
reached only within 2 h. In order to overcome this problem, individual samples were 
prepared by the addition of various amounts of KOH, and the actual pH, the UV-vis 
and 
1
H NMR spectra were always measured only after 4 h. Based on the recorded 
spectra (Figures 4 and S12) it could be concluded that the complex formation proceeds 
in a great extent already at pH 2. According to the 
1
H NMR (and UV-vis) spectra no 
free ligand and organometallic ion are found at pH ~2 with both Me-pyrTSC and Ph-
pyrTSC. No complex decomposition was found even at 10 M concentration by UV-
d
6.15 5.85 5.55 5.25
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+
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
16 
 
vis spectrophotometry. That is the reason why only a lower limit could be estimated for 
the formation constants of complexes those are present at this pH (Table 2). Smaller 
changes are observed in the pH range 2.1 ‒ 4.2 and 10.6 ‒ 12.1 in the UV-vis spectra 
(Figure S12) with the appearance of isobestic points representing the equilibrium 
processes between two species in both pH ranges. 
 
 
Figure 4. Representative 
1
H NMR spectra recorded for [Ru(6-p-cymene)(H2O)3]
2+
 ‒ Ph-pyrTSC (1:1) 
system in the pH range 2.2 ‒ 11.2 in the presence of 0.1 M chloride ions in 30% (v/v) DMSO-d6/water 
solvent mixture. Symbols: pyrazolyl-CH protons (●,○); thiosemicarbazone –CH= protons (▲,∆); 
pyrazolyl N-phenyl CH protons (■,□,♦,◊); p-cymene aromatic CH protons (a-h); free p-cymene (in the 
blue frame) and non-identified peaks (pink rectangle). {cRu(6-p-cymene) = 0.5 mM; T = 25.0 °C; I = 0.1 M 
(KCl)}  
 
Two sets of signals of pyrazolyl-CH and the thiosemicarbazone –CH= protons of 
the coordinated ligand are seen undoubtedly in the 
1
H NMR spectra (Figure 4). The 
minor species at pH 2.2 (shown with symbols ● and ▲) becomes predominant with 
increasing pH and the chemical shifts of its peaks remain constant; while the upfield 
shift of the peaks belonging to the major species (○ and ∆) is observed in the acidic pH 
range. On the other hand the peaks of the aromatic CH protons of the p-cymene moiety 
show quadruplicated signals (as well as the signals of the isopropyl-methyl group). The 
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chemically equivalent protons become magnetically inequivalent most probably as a 
consequence of the restricted rotation of the arene ring. Based on these findings we 
concluded that in the species predominating at pH 2.2 the ligand is coordinated in its 
HL form in a mononuclear complex and the deprotonation of the hydrazinic-NH 
results in the upfield shift of the NMR signals. This process could be characterized by 
a pKa = 3.44 value (Table 2). The complex characterized by the constant chemical shift 
is assumed to be a dinuclear species [(Ru(6-p-cymene))2(L)2]
2+
 in which both ligands 
coordinate via an (N,S
‒
) donor set while the sulphur atoms act as -bridging ligands. 
The suggested structures of the various complexes are presented in Chart 2. X-ray 
structures of dimeric -thiolato bridged Ru(6-p-cymene)-TSC complexes in solid 
phase have been already reported in the literature [56]. Based on the 
1
H NMR spectral 
data stepwise stability constants for the formation of the dimeric complexes from the 
mononuclear species could be computed (Table 2). Notably, the ratio of the peak 
integrals of the mononuclear and dinuclear species was not changed by varying the 
metal-to-ligand ratios at pH 2.7 and no other species appeared (besides the unbound 
organometallic cation or the free ligand at metal or ligand excess, respectively). 
However, new peaks were observed at pH > 10.6 and precipitate was also formed most 
probably due to the formation of a neutral mixed hydroxido species [Ru(6-p-
cymene)(L)(OH)] as it was observed in case of the complexes of other bidentate ligand 
[57]. A low intensity doublet peak appeared at 7.2 ppm that is typical to the free p-
cymene representing the release of the arene ligand.  
In order to further corroborate the co-existence of the mononuclear and dinuclear 
species, a dilution series was prepared in the concentration range 11.3‒450 M at pH 
7.4 and UV-vis spectra were recorded from which molar absorbance spectra were 
calculated (Figure S13). As level of dissociation increases with dilution, formation of 
higher fraction of mononuclear species is favoured at lower concentration compared to 
the dimer. It was found that the spectral characteristics altered significantly upon 
dilution suggesting the changed ratio of the mononuclear and dimeric complexes. In 
addition ESI-MS spectra were recorded for the [Ru(6-p-cymene)(H2O)3]
2+
 ‒ Ph-
pyrTSC system at 4 equivalents of ligand excess (Figure 5). The major species is the 
mononuclear complex, and some dinuclear and bis-ligand complexes were also found, 
although formation of the latter species could not be proved by the 
1
H NMR 
measurements (vide supra). 
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Based on the equilibrium constants determined it was concluded that complexes 
[Ru(6-p-cymene)(HL)(H2O/Cl)]
2+/+
, [Ru(6-p-cymene)(L)(H2O/Cl)]
+/0
 (the exact 
charges of these species are not known due to the partial coordination of the chloride 
ion) and [(Ru(6-p-cymene))(L)2]
2+
 are formed at pH 2 ‒ 4.3, while the latter two 
species are present up to pH ~ 9 (see representative concentration distribution curves in 
Figure S14). The predominant species is [(Ru(6-p-cymene))2(L)2]
2+
 at neutral pH. No 
significant differences in the solution speciation were found between the two studied 
TSC ligands.  
       
 
Chart 2. Suggested structures of the Ru(6-p-cymene) complexes of Me-pyrTSC and Ph-pyrTSC. 
Exact charges of the mononuclear species are not known due to the partial coordination of the chloride 
ion. 
S
Ru
H2O/ClN
HN
NH2
R
2+/+
S
Ru
H2O/ClN
N
NH2
R
+/0
S
Ru
N
N
NH2
R
S
Ru
N
N
H2N
R
2+
N
N
H3C
R =
N
N
[(Ru(6-p-cymene))2(L)2]
2+
[Ru(6-p-cymene)(HL)(H2O/Cl)]
2+/+
[Ru(6-p-cymene)(L)(H2O/Cl)]
+/0
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Figure 5. ESI-MS spectra recorded for the [Ru(6-p-cymene)(H2O)3]
2+
 ‒ Ph-pyrTSC (1:4) system. 
Peaks identified: [Ru(6-p-cymene)(L)]+ (a); [Ru(6-p-cymene)(L)2H]
+ 
(b); [(Ru(6-p-cymene))2(L)2‒
H]
+ 
and [(Ru(6-p-cymene))2(L)2Cl]
+ 
(c). {cRu(6-p-cymene) = 5.2 M; cL = 20.8 M; pH ~ 6; 2% (v/v) 
ethanol/water} 
 
We have attempted to study the solid phase structure of the Ru(6-p-cymene) complexes 
of the TSCs. Solid complexes [Ru(6-p-cymene)(TSC)Cl]Cl (where TSC = Me-pyrTSC or Ph-
pyrTSC) could be obtained from 2:1 mixtures of the ligand and the metal precursor prepared in 
ethanol:water mixture. Detailed characterization of the synthesized complexes is found in the 
SI. 
1
H and 
13C NMR spectra recorded for the [Ru(η6-p-cymene) complexes undoubtedly reveal 
that neither the free metal precursor nor the ligand is present in the solution, peaks assigned 
exclusively to the complex are observed. Single crystals of mononuclear [Ru(6-p-
cymene)(Me-pyrTSC)Cl]Cl (II) complex could be obtained as well and its crystal structure has 
been determined by single crystal X-ray diffraction. Notably, the isolated complexes contain 
the neutral ligands coordinated. II crystallized with one chloride counter ion in monoclinic P 
21/a space group and its ORTEP representation is depicted in Figure 6 and the unit cell is 
shown in Figure S15. Disordered structures have been found with disordered positions of the 
coordinated chlorido ligand as well as the isopropyl group and the phenyl-pyrazol moiety of 
the ligand (Figure 6, S16-S18). 
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Figure 6. Molecular structure of [Ru(6-p-cymene)(Me-pyrTSC)Cl]Cl (II). Displacement parameters 
are drawn at 50% probability level. Hydrogen atoms are omitted for clarity.  
The two positions are denoted by ’A’ and ’B’ and the occupancy ratio between the two 
positions was 67% and 33%, respectively. Disordered atoms of C19, C20, C21 and C6B were 
refined with isotropic displacement parameters. The Cl2 counter ion is involved in a hydrogen 
bond with N2-H2 proton, and thus this part of the molecule is relatively fixed (Figure S16). 
The disordered phenyl rings are turning towards each other forming columns in the crystal 
where they can occupy two main positions. In the case of the ‘A’ position the phenyl rings are 
arranged parallel to each other (the angle between the ring planes is 6.5°) and … stacking 
interaction is formed between the rings (Figure S17.a). For the minor position ‘B’, the phenyl 
ring planes form an angle of 86.4° in order to evolve a C-H… connection between the 
neighbouring rings. This interaction is further stabilized by a … stacking interaction 
between phenyl and adjacent pyrazol rings (Figure S17.b). Hydrogen bonds towards the 
chloride counter ion stabilize the packing arrangements in the crystal (Figure S18.a) in addition 
to an intramolecular hydrogen bond between an isopropyl C20A-H20B and chloride ion Cl1A 
(Figure S18.b). Selected H-bond distances and angles are collected in Table S4. Notably single 
crystals of [Ru(6-p-cymene)(Ph-pyrTSC)Cl]Cl were also obtained, however the level of 
disordered structures was even higher (not shown).   
 
3.3. Solution equilibrium and structural studies of copper(II) complexes 
Solution stability of Cu(II) complexes of numerous TSCs has been already characterized in 
our previous works [12-14,24]; however these compounds were tridentate ligands, namely -
N-pyridyl TSCs with (N,N,S) or salicylaldehyde TSCs with (O,N,S) binding modes, 
respectively. Despite the fact that Cu(II) complexes of bidentate TSCs are also widely 
investigated regarding their anticancer, antibacterial, antiviral properties and solid structures 
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[2,7], solution speciation data are hardly available for them in the literature. Herein complex 
formation equilibrium processes of Me-pyrTSC and Ph-pyrTSC with Cu(II) were 
characterized spectrophotometrically in 30% (v/v) DMSO/H2O. Bz-TSC was also involved 
for comparison. Representative UV-vis spectra recorded for Cu(II) ‒ Me-pyrTSC system in 
the pH range 2.5‒10 are shown in Figure 7 (and in Figure S19 for Bz-TSC complexes). 
Although fairly low ligand concentrations were used (10‒44 M), precipitation was observed 
at pH > ~6 using both 1:1 and 1:2 metal-to-ligand ratios. Notably in the Cu(II) ‒ Bz-TSC 
(1:2) system the precipitate occurred at somewhat higher pH (~9). Spectra were also recorded 
at constant pH (4.6) and constant ligand (10 M) or metal ion (10 M) concentrations varying 
the metal-to-ligand ratios (1:5-5:1). 
 
 
Figure 7. UV-vis absorption spectra of the Cu(II) ‒ Me-pyrTSC (1:2) system in the pH range 2.52-
10.04 in 30% (v/v) DMSO/water solvent mixture. (Dashed line show the spectra recorded in the pH 
range of precipitate formation.) Inset shows the molar absorbance spectra of HL, [Cu(L)]
+
 and 
[Cu(L)2] species. {cMe-pyrTSC = 10 M; cCu(II) = 5 M; T = 25.0 °C; I = 0.1 M (KCl); l = 1 cm}  
 
Stability constants for [Cu(L)]
+
 and [(Cu(L)2] complexes were computed by the 
deconvolution of the UV-vis spectra obtained for samples without precipitation (Table 3, 
Figure 7). These data reveal the considerably higher stability of the pyrazolyl complexes 
compared to that of Bz-TSC species. On the other hand all these bidentate TSCs preferably 
form bis-ligand complexes, which are neutral species with rather low water solubility. 
Significant fraction of bis complexes are present in the solution even at 1:1 ratio (Figure 8.a). 
On the contrary the salicylaldehyde TSCs form exclusively mono complexes [14]. However, 
bis and dinuclear complexes are also formed with -N-pyridyl TSCs besides the 
predominating mono complexes, but only at ligand excess, and at 1:1 ratio they do not appear 
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in the solution as the concentration distribution curves show for the Cu(II) ‒ Triapine (1:1) 
system in Figure 8.b.        
 
Table 3  
Overall stability constants (log) of the Cu(II) complexes formed with the studied ligands for 
comparison determined by UV-vis titrations. {T = 25 C; I = 0.1 M (KCl); 30% (v/v) DMSO/H2O}
 
 Me-pyrTSC Ph-pyrTSC Bz-TSC 
log[Cu(L)]+ 12.22±0.03 12.57±0.08 10.94±0.06 
log[(Cu(L)2] 24.89±0.09 25.53±0.09 21.49±0.09 
 
 
Figure 8.
 
Concentration distribution curves calculated for the Cu(II) ‒ Me-pyrTSC system based on 
the stability constants determined (a) (dashed lines show the pH range where precipitation occurs); and 
for Cu(II) ‒ Triapine system based on data taken from Ref. [12] (b). {cL = cCu = 10 M; T = 25.0 °C; I 
= 0.1 M (KCl); 30% (v/v) DMSO/H2O} 
 
Most probably as a consequence of the favourable formation of bis-ligand complexes in 
solution, [Cu(Me-pyrTSCH‒1)2] and [Cu(Ph-pyrTSCH‒1)2] could be isolated from a 
water:DMSO mixture at higher concentrations. The characterization of the synthesized 
complexes was performed by EPR spectroscopy, ESI-MS and UV-vis spectrophotometry. The 
experimental data and spectra collected can be found in the SI. The data strongly support the 
suggested structures. It should be noted that the isotropic EPR spectra show that the bis-ligand 
copper(II) - complexes of Ph-pyrTSC and Me-pyrTSC are present in 100% in DMSO solution. 
Free copper or mono-complex formation could not be detected. The low go values reflect high 
ligand field in the complexes. The EPR spectra could be described by taking into account two 
equivalent nitrogen splittings. Furthermore, single crystals for [Cu(Ph-pyrTSCH‒1)2] (III) 
could be obtained. The crystal structure has been determined by X-ray diffraction, and the 
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ORTEP representation is depicted in Figure 9. Complex III crystallized in the triclinic P-1 
space group. The asymmetric centre contains one bis-ligand complex and the half of another 
one which is mirrored by an inversion centre in the position of Cu2. The Cu(II) ions have 
square planar arrangements, the closest axial distance of 3.414 Å can be measured between 
Cu1 and S1 atom of neighbouring complex. The Cu-Cu closest distances are 4.350 Å for Cu1-
Cu1 and 5.490 Å for Cu1-Cu2. The phenyl rings are turning out of the pyrazole ring planes 
with 14.6(5)° for ring (C12-C17) and 37.8(4)° for ring (C5-C10) and for the other ligand 
17.7(4)° for ring (C32-C37) and 30.9(4)° for ring (C25-C30). For the symmetrical complex 
these values are 15.6(4) for ring (C52-C57) and 40.0(4) for ring (C45-C50). The arrangements 
are stabilized by hydrogen bonds (Table S5) between N11-H11A…S2 and C6-H6…N25 and 
by several … stacking interactions (three of them are below 4 Å) that arrange the molecules 
above each other (Figures S20, S21). Owing to the steric hindrance with the possible N or S 
acceptors, the phenyl protons are not involved in any hydrogen bonds, except of C6-H6…N25 
(Figure S20). 
 
 
Figure 9. Molecular structure of [Cu(Ph-pyrTSCH‒1)2] (III). Displacement parameters are drawn at 
50% probability level. Hydrogen atoms are omitted for clarity.  
 
3.4. In vitro cytotoxicity and antioxidant properties 
In order to evaluate the anticancer properties of Me-pyrTSC, Ph-pyrTSC, Ph-pyrSC and their 
Ru(II)(η6-p-cymene) and Cu(II) complexes, as a first step a cytotoxicity colorimetric MTT 
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assay was applied in doxorubicin-sensitive (Colo205) and multidrug resistant (Colo320) 
human colonic adenocarcinoma cell lines. The resistance of Colo320 cells is primarily 
mediated by the overexpression of ABCB1 (P-glycoprotein), a member of the ATP-binding 
cassette (ABC) transporter family, which pumps out xenobiotics from the cells. In addition, 
cytotoxicity was measured in normal human embryonal lung fibroblast cells (MRC5). The 
determined IC50 values are collected in Table 4. The corresponding metal ions as CuCl2 and 
the precursor [Ru(η6-cymene)Cl(μ-Cl)]2 were also tested for comparison. The complexes of 
the ligands were prepared in a 90% (v/v) DMSO/water mixture in situ by mixing the ligand 
with one or half equimolar concentration of the organometallic cation or Cu(II). In case of the 
Ru(II)(η6-p-cymene) complexes always 1:1 metal-to-ligand ratio was used, while Cu(II) 
complexes were tested at 0.5:1 ratio as well to ensure the formation of bis complexes. In the 
final samples the DMSO content was always lower than 1%. Cisplatin was used as a positive 
control.  
 
Table 4. In vitro cytotoxicity (IC50 values in M) of Me-pyrTSC, Ph-pyrTSC, Ph-pyrSC and their 
Ru(II)(6-p-cymene) and Cu(II) complexes in Colo205, Colo320 and MRC-5 cell lines. {72 h 
exposure} 
IC50 (M) Colo205  Colo320 MRC-5 
Cu(II) 
a
 23.9 ± 5.1 15.5 ± 0.8 16.0 ± 6.6 
Ru(6-p-cymene) b > 100 > 100 > 100 
Me-pyrTSC 49.6 ± 2.5 75.6 ± 13.5 > 100 
Ph-pyrTSC 50.0 ± 5.7 32.9 ± 2.6 > 100 
Ph-pyrSC 69.8 ± 6.9 74.4 ± 11.8 > 100 
Cu(II)-Me-pyrTSC (1:1) 6.27 ± 1.53 2.99 ± 0.77 6.79 ± 2.64 
Cu(II)-Me-pyrTSC (0.5:1) 5.88 ± 1.14 5.17 ± 1.06 10.2 ± 3.9 
Cu(II)-Ph-pyrTSC (0.5:1) 5.05 ± 0.94 4.16 ± 0.64 11.9 ± 2.0 
Cu(II)-Ph-pyrSC (0.5:1) 43.1 ± 5.8 28.8 ± 1.9 73.7 ± 10.6 
Ru(6-p-cymene)-Me-pyrTSC (1:1) 23.8 ± 5.8 12.40 ± 5.4 32.0 ± 7.1 
Ru(6-p-cymene)-Ph-pyrTSC (1:1) 11.9 ± 3.4 11.2 ± 4.8 24.7 ± 2.2 
Ru(6-p-cymene)-Ph-pyrSC (1:1) 42.2 ± 9.2 48.5 ± 10.0 56.6 ± 8.4 
Cisplatin 60.4 ± 9.5 25.4 ± 2.5 55.7 ± 10.6 
a Stock solution prepared by dissolution of CuCl2. 
b Stock solution prepared by dissolution of 
[Ru(6-p-cymene)(-Cl)Cl]2. 
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The Ru(η6-p-cymene) precursor did not show cytotoxic effect, while CuCl2 was moderately 
toxic in the tested cell lines. The ligands were not cytotoxic against the normal fibroblast 
cells, while IC50 values in the range 33‒76 M were obtained in both human adenocarcinoma 
cell lines. In the presence of both Ru(η6-p-cymene) and Cu(II) lower IC50 values were 
determined compared to the respective ligands as a consequence of the complex formation; 
however, the Cu(II) complexes were much more cytotoxic in the case of the 
thiosemicarbazones. The complex formation with the metal ions always resulted in greater 
activity than cisplatin. The Cu(II) and Ru(η6-p-cymene) complexes showed selectivity against 
the cancer cells compared to the normal cells in all cases, moreover complexes of Me-pyrTSC 
at 1:1 metal-to-ligand ratio revealed a measurable selectivity against the multidrug resistant 
cancer cell line (Colo320) over the Colo205 cells. 
Since the studied TSCs were highly synergistic with CuCl2, and the higher cytotoxic 
activity of certain TSCs is associated with induction of reactive oxygen species [17,18], Me-
pyrTSC, Ph-pyrTSC and their Cu(II) complexes were further investigated regarding their 
intracellular ROS production, catalase activity and their effect on cellular GSH level. These 
assays were performed in various breast cancer cells for the ligands and for the complexes as 
well. Cytotoxicity was also measured in the hormone-responsive MCF7, the HER2-positive 
SkBr3 and the triple-negative SUM159 breast cancer cell lines, in addition to the 
hepatocellular carcinoma cell line (HepG2), and the in vitro cytotoxicity data are shown in 
Table 5. Similarly to the Colo205 and Colo320 cell lines, the ligands exhibited undoubtedly 
synergistic effect with the Cu(II) io s. The Cu(II) salt and the ligands were less toxic against 
these cell lines compared to Colo205/320. The complexation resulted in higher cytotoxicity in 
the SkBr3 and SUM159 cells.  
 
Table 5. In vitro cytotoxicity (IC50 values in M) of Me-pyrTSC, Ph-pyrTSC and their Cu(II) 
complexes in MCF7, SkBr3, SUM159 and HepG2 cell lines. {24 h exposure} 
 MCF7  SkBr3 SUM159 HepG2 
Cu(II) 
a
 > 100 > 50 73.69 ± 0.52 > 50 
Me-pyrTSC > 100 > 50 > 100 > 50 
Ph-pyrTSC > 100 24.5 ± 2.2 40.6 ± 1.5 > 50 
Cu(II)-Me-pyrTSC (0.5:1) 19.1 ± 2.0 5.85 ± 0.53 6.54 ± 0.13 12.0 ± 1.8 
Cu(II)-Ph-pyrTSC (0.5:1) 18.9 ± 2.0 4.01 ± 0.26 4.22 ± 0.27 21.68 ± 0.20 
a Stock solution prepared by dissolution of CuCl2.  
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In order to investigate the basis of cytotoxicity, ROS production was measured in MCF7 
and SUM159 cell lines using the ROS sensitive cell permeable dye DCFDA (Figure S22, Table 
S6). Results are expressed as fold change in the emission intensities after exposure to the test 
compound relative to the solvent control (without the use of NAC). The ligands and their 
Cu(II) complexes showed no ability to produce ROS under the applied conditions (1 M ligand 
concentration where the compounds are non-cytotoxic, 120 min incubation time); moreover all 
showed weak antioxidant activity as somewhat lower intensities were measured compared to 
those of the solvent blank. Addition of the reducing agent NAC decreased the ROS production 
in the control samples and almost in all cases of the compounds tested (except Me-pyrTSC 
with and without Cu(II) in SUM159 cell); however, the decrease of the intensity was more 
significant in case of the MCF7 cells. 
 
 
Figure 10. Catalase activity (a) and GSH level (b) in MCF7 (grey bars) and SUM159 (red bars) cells 
measured for the control (without the addition of any solvent or compound), solvent control 
(background DMSO/buffer mixture as in the samples tested), CuCl2 (0.5 M) and for the ligands 
(1 M) in the absence and in the presence of half equivalent Cu(II) (0.5 M). Values show the mean 
of two experiments (see data in Table S7).  
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Catalase is an antioxidant enzyme converting H2O2 to water and oxygen, thus it is able to 
protect cells against H2O2 stress. Catalase activity was measured in MCF7 and SUM159 cell 
lines in order to characterize the antioxidant status of the cells and results are shown in Figure 
10.a. Different effect was observed for the two kinds of cell lines, namely the ligands and the 
Cu(II) complexes revealed similar and low catalase activity in MCF7 cells, while increased 
catalase activity was seen in SUM159 cells. However, comparing the behaviour of the 
compounds to solvent control, a decreased activity was detected in the latter cells. Notably, the 
compounds were more cytotoxic in SUM159 than in MCF7 cells (see IC50 values in Table 5), 
thus the increased catalase activity did not protect the SUM159 cells against the toxicity of the 
tested compounds. Disturbances in GSH homeostasis are often involved in progression of 
cancer [58]. The decrease in the GSH level can lead to an increased susceptibility to oxidative 
stress, while the elevated GSH concentration increases the antioxidant capacity and can 
consequently increase the resistance to oxidative stress. Based on the data obtained for the 
GSH levels (Figure 10.b) the monitored two untreated cell lines exhibited similar values. 
Addition of both the solvent DMSO mixture and CuCl2 resulted in increased GSH content in 
SUM159 cells, and they did not affect the GSH l vel in MCF7. The tested compounds (Me-
pyrTSC, Ph-pyrTSC and their Cu(II) complexes) had different effects, since the GSH level was 
decreased in SUM159 cells, while increased GSH concentration was measured in the MCF7 
cells compared to the controls. No significant changes were seen upon addition of Cu(II) to the 
ligands.  
These results suggest that the tested compounds may cause changes in antioxidant 
transcription factor Nrf2, which is responsible for transcription of enzymes needed for GSH 
synthesis [59] independently of ROS production. Certainly, as these two cell lines represent 
breast cancer of different malignancy with different metabolic capacities, it would be 
interesting to investigate in the near future how these differences occur in the light of therapy 
resistance. 
 
4. Conclusions  
Solution speciation, solid phase structure and anticancer properties of two bidentate pyrazolyl 
thiosemibarbazones Me-pyrTSC, Ph-pyrTSC and their Cu(II) and Ru(6-p-cymene) 
complexes were investigated. The characterization of the proton dissociation processes by 
UV-vis spectrophotometry in partially aqueous solution revealed that the ligands are present 
in their neutral form in a wide pH range (up to pH ~10), as the deprotonation of the hydrazinic 
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NH moiety takes place only in the basic pH range (pKa: 11.53 (Me-pyrTSC), 11.78 (Ph-
pyrTSC)). This feature also contributes to the strongly lipophilic character of the ligands. The 
stoichiometry and stability of the Cu(II) and Ru(6-p-cymene) complexes were studied in 
30% (v/v) DMSO/H2O solvent mixture with a focus on the most plausible species that 
emerged at physiological pH. For the solution speciation studies mainly UV-vis 
spectrophotometry was used and 
1
H NMR spectroscopy and ESI-MS were also applied for the 
Ru(6-p-cymene) complexes. The complex formation with Cu(II) was found to be fast, while 
longer waiting time (>1.5 h) was necessary to reach the complete equilibrium in case of the 
Ru(6-p-cymene) species. 
 Based on the solution equilibrium studies we concluded that mononuclear [Ru(6-p-
cymene)(HL)(Z)]
2+/+ 
and [Ru(6-p-cymene)(L)(Z)]+/0 species are formed at pH < 4 (where Z= 
H2O/DMSO or Cl
‒
), while a dinuclear [(Ru(6-p-cymene))2(L)2]
2+
 complex becomes 
predominating at higher pH values including the physiological pH. These complexes possess 
significantly high solution stability. In [Ru(6-p-cymene)(HL)]2+/+ the ligand coordinates in 
its neutral form via (N,S) donor set and [Ru(6-p-cymene)(L)]+/0 is formed by the 
deprotonation of the hydrazinic nitrogen (pKa: 3.50, 3.44 for Me-pyrTSC, Ph-pyrTSC, 
respectively). The (N,S
‒
) coordination mode in the latter species was confirmed by X-ray 
crystallography. Most probably the ligands also coordinate via the (N,S
‒
) donor set in the 
dinuclear [(Ru(6-p-cymene))2(L)2]
2+
 complex, although the sulphur atoms act as -bridging 
ligands between the two metal centres. Cu(II) forms mono [CuL]
+
 and bis [CuL2] complexes 
with the studied pyrazolyl thiosemibarbazones and their reference compound Bz-TSC. 
Formation of [CuL2] is favourable at neutral pH and these complexes are characterized by 
poor water solubility. X-ray diffraction study of [Cu(Ph-pyrTSCH‒1)2] showed the bidentate 
coordination of the ligands via (N,S
‒
) donor set with deprotonated hydrazinic nitrogens. The 
observed trend for the stability of the Cu(II) complexes is the following: Ph-pyrTSC > Me-
pyrTSC >> Bz-TSC, thus the presence of the pyrazolyl moiety undoubtedly increased the 
solution stability.  
 In vitro cytotoxicity of Me-pyrTSC, Ph-pyrTSC and the semicarbazone Ph-pyrSC, as 
well as of their Cu(II) and Ru(6-p-cymene) complexes was measured in a cell line pair, 
namely in Colo205 (human colonic adenocarcinoma) and its multidrug resistant counterpart 
Colo320. Toxicity of the compounds was also monitored in a human embryonal lung fibroblast 
cell line (MRC-5). The tested ligands showed moderate cytotoxicity against the cancerous 
cells, but were not toxic against MRC-5. Complexation with the metal ions has increased the 
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cytotoxic activity in all cases, and a stronger synergism was observed in case of the 
thiosemicarbazones. The most active Cu(II) complexes and their ligands were further 
investigated. Cytotoxicity of Me-pyrTSC, Ph-pyrTSC in the absence and in the presence of 
Cu(II) ions was screened in three breast cancer cell lines (MCF7, SkBr3, SUM159) and in a 
hepatocellular carcinoma cell line (HepG2). The Cu(II) complexes were found to be again 
more active than their ligands. No ROS production was detected in MCF7 and SUM159 cells 
at 1 M concentration of the compounds and they did not affect significantly the catalase 
activity in MCF7 cells. The SUM159 cells have relatively high catalase activity, but it was 
diminished upon addition of the tested compounds. The compounds resulted in a decreased 
GSH level in SUM159 cells, while higher GSH concentration was seen in the MCF7 cells 
comparing to the controls. It suggests that the studied compounds interfere with the GSH 
synthesis without ROS production. However, the Cu(II) complexation did not bring differences 
in the GSH levels.  
            
5. Abbreviations 
Bz-TSC benzaldehyde thiosemicarbazone 
D7.4 distribution coefficients 
DCF 2,7-dichlorofluorescein 
DCFH-DA 2,7-dichlorodihydrofluorescein diacetate 
DMEM Dulbecco’s modified Eagle’s medium 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DSS 4,4-dimethyl-4-silapentane-1-sulfonic acid 
DTNB 2,2'-dinitro-5,5'-dithiodibenzoic acid, Ellman’s reagent 
ESI-MS electrospray ionization mass spectrometry 
EtOAc ethyl acetate 
EtOH ethanol 
FBS fetal bovine serum 
GSH L-glutathione 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Me-pyrTSC 2-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)hydrazinecarbothioamide 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW microwave 
NAC N-acetyl-cysteine 
OD optical density 
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PBS phosphate buffer saline 
Ph-pyrSC 2-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)hydrazinecarboxamide 
Ph-pyrTSC 2-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)hydrazinecarbothioamide 
ROS reactive oxygen species 
RPMI Roswell Park Memorial Institute 
TLC thin-layer chromatography 
Triapine 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 
TSC thiosemicarbazone 
UV-vis UV-visible 
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Synopsis  
 
Solution stability of anticancer Ru(II)(6-p-cymene) and Cu(II) complexes of two bidentate 
pyrazolyl thiosemicarbazones (TSC) was determined, and three structures were resolved by 
X-ray diffraction. [(Ru(6-p-cymene))2(TSC)2]
2+
 and [Cu(TSC)2] complexes are the dominant 
species at neutral pH. The metal complexes are more cytotoxic than the ligands. 
 
Graphical abstract  
 
 
  
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
36 
 
Highlights 
 
Solution stability of Ru(cymene) and Cu(II) pyrazolyl thiosemicarbazone complexes  
Dinuclear Ru(cymene) species with (N,S) donor and 2-bridging S atoms at neutral pH 
[CuL2] with (N,S)(N,S) donor set predominates at neutral pH 
Solid phase structures of two complexes and one ligand resolved by X-ray diffraction  
More cytotoxic metal complexes than the ligands in various human cancer cell lines 
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